Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Neurofibrosarcoma 1Melanoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Fibrosarcoma 1Endometrial Neoplasms 1

Interventions

Interferon-alpha 6Radiosurgery 4Dacarbazine 4encorafenib 3binimetinib 3aldesleukin 3Immunohistochemistry 3Gene Expression Profiling 3Filgrastim 3Cisplatin 3X-Rays 2Watchful Waiting 2Vinblastine 2Temozolomide 2Specimen Handling 2Radiotherapy 2Polymerase Chain Reaction 2Observation 2Nivolumab 2Ipilimumab 2Immunologic Techniques 2Flow Cytometry 2trametinib 1sulforaphane 1sargramostim 1romidepsin 1perifosine 1pembrolizumab 1peginterferon alfa-2b 1montanide ISA 51 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Melanoma × perifosine × Clear all
NCT00053781 2023-08-04

Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Canadian Cancer Trials Group

Phase 2 Completed
18 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡